Achillion: William Blair & Company 2016 Growth Stock Conference (Achillion) - Jun 18, 2016 - Anticipated initiation of P2b trial evaluating doublet and triplet regimens of odalasvir with AL-335 and/ simeprevir in hepatitis C infection with or without cirrhosis in Q3 2016
Anticipated trial initiation date • Hepatitis C Virus
|